Hangzhou Kang Ming Information Technology Co., Ltd (HKG: 9955), known as “ClouDr,” has partnered with French pharmaceutical company Ipsen S.A. (Euronext: IPN; ADR: IPSEY) regarding Ipsen’s Diphereline (triptorelin), a natural gonadotropin-releasing hormone (GnRH) agonist analog. Financial details of the partnership were not disclosed. ClouDr is a one-stop chronic disease management and smart healthcare platform with a SaaS system covering nearly 2,000 hospitals in China, a pharmacy system serving 130,000 pharmacies, and an internet hospital subscribed to by nearly 50,000 physicians.
Product Background
Diphereline, developed by Ipsen, is commercially available in over 80 countries globally for the treatment of prostate cancer, central childhood precocious puberty, assisted reproduction, endometriosis, and other conditions. The partnership aims to leverage ClouDr’s offline access capabilities to enhance the comprehensive coverage of the drug in China, benefiting more patients in the country.-Fineline Info & Tech
